New vaccine combo shows promise for tough bladder cancer
NCT ID NCT05843448
First seen Mar 26, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This early-stage trial tests a new vaccine (IO102-IO103) plus the immunotherapy drug pembrolizumab in 30 adults with a high-risk bladder cancer that did not respond to or could not tolerate standard BCG therapy. The vaccine aims to train the body's immune cells to recognize and attack the cancer, while pembrolizumab helps the immune system fight harder. The main goal is to check safety and side effects, with a secondary goal of seeing if the cancer disappears completely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 0A BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.